Telix Pharmaceuticals (CHIA:TLX) - Stock Price, News & Analysis

TLX Stock Overview

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. More details

TLX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	6/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 48.2% below our estimate of its fair value

Earnings are forecast to grow 38.32% per year

Became profitable this year

Risk Analysis

Shareholders have been diluted in the past year

Telix Pharmaceuticals Limited Competitors

Race Oncology

ASX:RAC

AU$237.8m

Clinuvel Pharmaceuticals

ASX:CUV

AU$680.3m

CSL

ASX:CSL

AU$131.4b

Orthocell

ASX:OCC

AU$151.8m

Price History & Performance

Summary of all time highs, changes and price drops for Telix Pharmaceuticals
Historical stock prices
Current Share Price	AU$23.03
52 Week High	AU$23.99
52 Week Low	AU$9.07
Beta	2.38
11 Month Change	5.06%
3 Month Change	15.21%
1 Year Change	147.10%
33 Year Change	228.06%
5 Year Change	1,172.38%
Change since IPO	3,660.00%

Recent updates

Shareholder Returns

	TLX	AU Biotechs	AU Market
7D	-1.9%	-4.9%	0.4%
1Y	147.1%	9.9%	16.9%

Return vs Industry: TLX exceeded the Australian Biotechs industry which returned 9.9% over the past year.

Return vs Market: TLX exceeded the Australian Market which returned 16.9% over the past year.

Price Volatility

Is TLX's price volatile compared to industry and market?
TLX volatility
TLX Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: TLX has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: TLX's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	423	Chris Behrenbruch	telixpharma.com

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.

Telix Pharmaceuticals Limited Fundamentals Summary

How do Telix Pharmaceuticals's earnings and revenue compare to its market cap?
TLX fundamental statistics
Market cap	AU$7.70b
Earnings (TTM)	AU$49.19m
Revenue (TTM)	AU$645.68m

156.6x

P/E Ratio

11.9x

P/S Ratio

Is TLX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TLX income statement (TTM)
Revenue	AU$645.68m
Cost of Revenue	AU$240.33m
Gross Profit	AU$405.35m
Other Expenses	AU$356.16m
Earnings	AU$49.19m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.15
Gross Margin	62.78%
Net Profit Margin	7.62%
Debt/Equity Ratio	2.9%

How did TLX perform over the long term?

See historical performance and comparison

TLX Stock Overview

Rewards

Risk Analysis

Telix Pharmaceuticals Limited Competitors

ASX:RAC

AU$237.8m

ASX:CUV

AU$680.3m

ASX:CSL

AU$131.4b

ASX:OCC

AU$151.8m

Price History & Performance

Recent News & Updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Recent updates

Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy

Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million.

Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent

Second quarter 2024 earnings released: EPS: AU$0.035 (vs AU$0.018 loss in 2Q 2023)

Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent

Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024

Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million.

First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023)

Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent

Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million.

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Now 20% overvalued after recent price rise

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022)

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million.

Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591

Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies

Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast breakeven date moved forward to 2023

Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023

Forecast to breakeven in 2023

Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023

Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Insider recently bought AU$343k worth of stock

Full year 2022 earnings released: AU$0.34 loss per share (vs AU$0.28 loss in FY 2021)

Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023

Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Insider recently bought AU$73k worth of stock

Telix Pharmaceuticals Limited Announces Leadership Changes

Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection

Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

Insufficient new directors

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center.

Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints

Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study